April 1st, 2011

Podcast 117: Atorvastatin and new-onset diabetes

(3 votes, average: 3.33 out of 5)

Statins, according to a 2010 meta-analysis in Lancet, are associated with a slightly increased risk for new-onset type 2 diabetes. One, atorvastatin (marketed as Lipitor), was underrepresented in that analysis. Researchers, along with the manufacturer, decided to have a look at data from three trials to see whether atorvastatin also conferred that risk. And, indeed they found that the risk was there — most especially in the SPARCL trial, which compared high-dose atorvastatin with placebo.

Our interview is with the first author of that later analysis, Dr. David D. Waters, of UCSF. His paper appeared earlier this week in the Journal of the American College of Cardiology.

Interview-related links:

Comments are closed.

Clinical Conversations

About the Podcast

To subscribe: Subscribe on iTunes

To have your comment included in a future podcast, call 617-440-4374. Please leave your name, number, and the podcast ID number.